Immunovant, Inc.
IMVT- Exchange
- Nasdaq
- Industry
- Biological Products, (No Diagnostic Substances)
- SEC CIK
- 0001764013
In the last 90 days, Immunovant, Inc. insiders filed 0 open-market purchases and 9 sales; 226 institutions reported holding it in 13F filings for Q2 2026, worth $4.25B in total; Greenlight Capital is the only superinvestor holding it.
Key figures
- Market capClose on Nov 9, 2026
- $7.26B
- Insider buysOpen market, last 90 days
- 0
- Insider sellsLast 90 days, $922.8K in total
- 9
- 13F holdersQ2 2026, +13 vs. previous quarter
- 226
- 13F valueReported value at the end of Q2 2026
- $4.25B
- Superinvestors holdingAt the end of Q2 2026
- 1
Price chart
Financials
See financial statementsFrom SEC filings, in USD.
- Revenue, FY2026
- –
- No comparable prior period
- Net income, FY2026
- -$505.6M
- No comparable prior period
- Free cash flow, FY2026
- -$407.3M
- No comparable prior period
- Revenue, Q2 FY2027
- –
- No comparable prior period
Short interest
See short dataFrom FINRA, settlement date Oct 15, 2026.
- Short interest
- 18.3M
- Shares sold short
- Change
- +857.1K
- +4.9% vs. previous
- Days to cover
- 12.35
- At average daily volume
Superinvestors holding IMVT, Q2 2026
Go to the superinvestors tab1 superinvestor reports holding Immunovant, Inc. on Form 13F. Percentages are the stock's share of each portfolio.
Latest insider trades
See all insider tradesOpen-market purchases and sales by Immunovant, Inc. insiders from Form 4, newest first.
| Filed (ET) | Trade date | Filing delay | Insider | Transaction | Shares | Avg price | Value | Holding change | Flags |
|---|---|---|---|---|---|---|---|---|---|
| Oct 30, 2026 (view filing)4:37 PM ET | Oct 28 | 2 days | Girao TiagoChief Financial Officer | SSale | −6.61K | $28.50 | −$188.3K | −2.7%234.2K after | |
| Oct 23, 2026 (view filing)4:55 PM ET | Oct 21 | 2 days | Stout Jay SChief Technology Officer | SSale | −2.60K | $28.94 | −$75.1K | −1.3%198.9K after | |
| Oct 9, 2026 (view filing)5:05 PM ET | Oct 7 | 2 days | Stout Jay SChief Technology Officer | SSale | −3.81K | $32.06 | −$122.1K | −1.9%201.5K after | 2 lots |
| Oct 9, 2026 (view filing)5:05 PM ET | Oct 7 | 2 days | Van Tuyl ChristopherChief Legal Officer | SSale | −1.33K | $32.06 | −$42.5K | −0.8%175.2K after | |
| Oct 9, 2026 (view filing)5:04 PM ET | Oct 7 | 2 days | Gloria MelanieChief Operating Officer | SSale | −2.24K | $32.06 | −$71.8K | −1.0%217.1K after | |
| Oct 5, 2026 (view filing)7:42 PM ET | Oct 2 | 3 days | Venker EricChief Executive Officer | SSale | −3.51K | $34.11 | −$119.6K | −1.3%257.1K after | |
| Sep 25, 2026 (view filing)4:05 PM ET | Sep 23 | 2 days | Van Tuyl ChristopherChief Legal Officer | SSale | −2.85K | $36.36 | −$103.5K | −1.6%176.5K after | |
| Aug 28, 2026 (view filing)4:27 PM ET | Aug 28 | Same day | Pande AtulDirector | SSale | −1.50K | $43.27 | −$64.9K | −1.3%116.7K after | 10b5-1 |
| Aug 21, 2026 (view filing)4:03 PM ET | Aug 20 | 1 day | Gloria MelanieChief Operating Officer | SSale | −3.06K | $44.16 | −$135.0K | −1.4%219.3K after | |
| Jul 24, 2026 (view filing)5:59 PM ET | Jul 24 | Same day | Pande AtulDirector | SSale | −1.50K | $39.80 | −$59.7K | −1.3%116.7K after | 10b5-1 |
Top 10 13F holders, Q2 2026
See all 226 holdersThe largest institutional positions in Immunovant, Inc. at the end of Q2 2026; share changes are against Q1 2026.
| Institution | Shares | Value | % of portfolio | Change in shares | Action |
|---|---|---|---|---|---|
| FMR LLC | 16,186,469 | $623.7M | 0.03% | −761,419−4.5% | Reduced |
| Deep Track Capital, LP | 9,341,151 | $359.9M | 5.30% | −2,185,820−19.0% | Reduced |
| BlackRock, Inc. | 7,180,897 | $276.7M | 0.00% | +606,400+9.2% | Added |
| Farallon Capital Management, L.L.C. | 5,805,000 | $223.7M | 1.31% | +4,259,000+275.5% | Added |
| Baker Bros. Advisors LP | 5,435,220 | $209.4M | 1.05% | −22,661−0.4% | Reduced |
| State Street Corp | 4,617,005 | $177.9M | 0.01% | +79,076+1.7% | Added |
| Morgan Stanley | 4,534,833 | $174.7M | 0.01% | +657,956+17.0% | Added |
| TCG Crossover Management, LLC | 4,457,988 | $171.8M | 4.13% | 00.0% | Unchanged |
| Vanguard Portfolio Management LLC | 3,910,509 | $150.7M | 0.01% | +205,604+5.5% | Added |
| Vanguard Capital Management LLC | 3,638,681 | $140.2M | 0.00% | +18,631+0.5% | Added |
Holders of 5% or more of IMVT
See all 2 holders and filingsHolders whose latest Schedule 13D or 13G filing reports 5% or more of Immunovant, Inc..
| Holder | Latest form | Stake | Change | First filed | Latest filing | Filing |
|---|---|---|---|---|---|---|
| Roivant Sciences Ltd. | 13D/A | 55.90%113.3M shares | −1.00 ppfrom 56.90% | Mar 8, 20216 filings | Dec 12, 2025 | SEC |
| FMR LLC | 13G/A | 8.40%14.7M shares | −1.70 ppfrom 10.10% | Feb 9, 20244 filings | Nov 5, 2025 | SEC |